Search

Your search keyword '"Engert, Andreas"' showing total 2,397 results
Start Over Author "Engert, Andreas"

Refine your results

2,397 results on '"Engert, Andreas"'

203. Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial

Author

Bröckelmann, Paul J, primary, Goergen, Helen, additional, Keller, Ulrich, additional, Meissner, Julia, additional, Trautmann, Karolin, additional, Halbsguth, Teresa V, additional, Sasse, Stephanie, additional, Sökler, Martin, additional, Kerkhoff, Andrea, additional, Mathas, Stephan, additional, Hüttmann, Andreas, additional, Bormann, Matthias, additional, Zimmermann, Andreas, additional, Fuchs, Michael, additional, von Tresckow, Bastian, additional, Baues, Christian, additional, Rosenwald, Andreas, additional, Klapper, Wolfram, additional, Kobe, Carsten, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2020
Full Text
View/download PDF

205. AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial

Author

Sasse, Stephanie, primary, Momotow, Jesko, additional, Plütschow, Annette, additional, Hüttmann, Andreas, additional, Basara, Nadezda, additional, Koenecke, Christian, additional, Martin, Sonja, additional, Bentz, Martin, additional, Grosse-Thie, Christina, additional, Thorspecken, Sven, additional, de Wit, Maike, additional, Kobe, Carsten, additional, Dietlein, Markus, additional, von Tresckow, Bastian, additional, Fuchs, Michael, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2020
Full Text
View/download PDF

218. Reinduction therapy with everolimus in combination with dexamethasone, high‐dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD‐R3i)

Author

Gillessen, Sarah, Hüttmann, Andreas, Vucinic, Vladan, Müller, Horst, Plütschow, Annette, Viardot, Andreas, Topp, Max S., Kobe, Carsten, Böll, Boris, Eichenauer, Dennis A., Sasse, Stephanie, Haverkamp, Heinz, Schmitz, Christine, Borchmann, Sven, Bröckelmann, Paul J., Heger, Jan‐Michel, Fuchs, Michael, Engert, Andreas, Borchmann, Peter, and von Tresckow, Bastian

Subjects
HODGKIN'S disease, EVEROLIMUS, STEM cell transplantation, DEXAMETHASONE, COMPUTED tomography
Abstract

Summary: Reinduction chemotherapy followed by high‐dose chemotherapy and autologous stem cell transplant (HDCT + ASCT) is second‐line standard of care for transplant‐eligible patients with relapsed/refractory classical Hodgkin lymphoma (r/r cHL) but has a high failure rate. Because response to reinduction is predictive of the outcome after HDCT + ASCT, we aimed to improve the standard dexamethasone, high‐dose cytarabine and cisplatinum (DHAP) reinduction regimen by addition of the oral mammalian target of rapamycin inhibitor everolimus (everDHAP). Transplant‐eligible patients aged 18–60 years with histologically confirmed r/r cHL were included in this experimental phase I/II trial. Everolimus (10 mg/day, determined in phase‐I‐part) was administered on day 0–13 of each DHAP cycle. From July 2014 to March 2018, 50 patients were recruited to the phase II everDHAP group; two were not evaluable, three discontinued due to toxicity. Randomization to a placebo group stopped in October 2015 due to poor recruitment after nine patients. The primary end‐point of computed tomography (CT)‐based complete remission (CR) after two cycles of everDHAP was expected to be ≥40%. With a CT‐based CR rate of 27% (n = 12/45) after two cycles of everDHAP the trial did not meet the primary end‐point. Adding everolimus to DHAP is thus feasible; however, the everDHAP regimen failed to show an improved efficacy. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

219. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.

Author

Gerhard‐Hartmann, Elena, Goergen, Helen, Bröckelmann, Paul J., Mottok, Anja, Steinmüller, Tabea, Grund, Johanna, Zamò, Alberto, Ben‐Neriah, Susana, Sasse, Stephanie, Borchmann, Sven, Fuchs, Michael, Borchmann, Peter, Reinke, Sarah, Engert, Andreas, Veldman, Johanna, Diepstra, Arjan, Klapper, Wolfram, and Rosenwald, Andreas

Subjects
PROGRAMMED death-ligand 1, HODGKIN'S disease, MANTLE cell lymphoma, MAJOR histocompatibility complex
Abstract

Summary: High programmed cell death 1 ligand 1 (PD‐L1) protein expression and copy number alterations (CNAs) of the corresponding genomic locus 9p24.1 in Hodgkin‐ and Reed–Sternberg cells (HRSC) have been shown to be associated with favourable response to anti‐PD‐1 checkpoint inhibition in relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In the present study, we investigated baseline 9p24.1 status as well as PD‐L1 and major histocompatibility complex (MHC) class I and II protein expression in 82 biopsies from patients with early stage unfavourable cHL treated with anti‐PD‐1‐based first‐line treatment in the German Hodgkin Study Group (GHSG) NIVAHL trial (ClinicalTrials.gov Identifier: NCT03004833). All evaluated specimens showed 9p24.1 CNA in HRSC to some extent, but with high intratumoral heterogeneity and an overall smaller range of alterations than reported in advanced‐stage or r/r cHL. All but two cases (97%) showed PD‐L1 expression by the tumour cells in variable amounts. While MHC‐I was rarely expressed in >50% of HRSC, MHC‐II expression in >50% of HRSC was found more frequently. No obvious impact of 9p24.1 CNA or PD‐L1 and MHC‐I/II expression on early response to the highly effective anti‐PD‐1‐based NIVAHL first‐line treatment was observed. Further studies evaluating an expanded panel of potential biomarkers are needed to optimally stratify anti‐PD‐1 first‐line cHL treatment. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

220. Histopathological growth patterns in patients with advanced nodular lymphocyte‐predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group.

Author

Eichenauer, Dennis A., Bühnen, Ina, Kreissl, Stefanie, Goergen, Helen, Fuchs, Michael, von Tresckow, Bastian, Rosenwald, Andreas, Klapper, Wolfram, Hansmann, Martin‐Leo, Möller, Peter, Bernd, Heinz‐Wolfram, Feller, Alfred C., Engert, Andreas, Borchmann, Peter, and Hartmann, Sylvia

Subjects
HODGKIN'S disease, POSITRON emission tomography, HISTOPATHOLOGY, PROGRESSION-free survival, OVERALL survival, NEUROECTODERMAL tumors
Abstract

Summary: We retrospectively investigated histopathological growth patterns in individuals with advanced nodular lymphocyte‐predominant Hodgkin lymphoma (NLPHL) treated within the randomized HD18 study. In all, 35/60 patients (58%) presented with atypical growth patterns. Patients with atypical growth patterns more often had stage IV disease (P = 0·0354) and splenic involvement (P = 0·0048) than patients with typical growth patterns; a positive positron emission tomography after two cycles of chemotherapy (PET‐2) tended to be more common (P = 0·1078). Five‐year progression‐free survival [hazard ratio (HR) = 0·86; 95% confidence interval (CI) = 0·49–1·47] and overall survival (HR = 0·85; 95% CI = 0·49–1·51) did not differ between the groups after study treatment with PET‐2‐guided escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone). Thus, advanced NLPHL is often associated with atypical growth patterns but their prognostic impact is compensated by PET‐2‐guided escalated BEACOPP. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

235. Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group

Author

Kreissl, Stefanie, primary, Müller, Horst, additional, Goergen, Helen, additional, Meissner, Julia, additional, Topp, Max, additional, Sökler, Martin, additional, Markova, Jana, additional, Bernhard, Jürg, additional, Greil, Richard, additional, von Tresckow, Bastian, additional, Behringer, Karolin, additional, Rüffer, Jens-Ulrich, additional, Flechtner, Hans-Henning, additional, Möstl, Michaela, additional, Fuchs, Michael, additional, Engert, Andreas, additional, Diehl, Volker, additional, and Borchmann, Peter, additional

Published
2020
Full Text
View/download PDF

236. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma

Author

Bröckelmann, Paul J., primary, Goergen, Helen, additional, Keller, Ulrich, additional, Meissner, Julia, additional, Ordemann, Rainer, additional, Halbsguth, Teresa V., additional, Sasse, Stephanie, additional, Sökler, Martin, additional, Kerkhoff, Andrea, additional, Mathas, Stephan, additional, Hüttmann, Andreas, additional, Bormann, Matthias, additional, Zimmermann, Andreas, additional, Mettler, Jasmin, additional, Fuchs, Michael, additional, von Tresckow, Bastian, additional, Baues, Christian, additional, Rosenwald, Andreas, additional, Klapper, Wolfram, additional, Kobe, Carsten, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2020
Full Text
View/download PDF

237. Safety of weight-based dosing of nivolumab with or without ipilimumab by body mass index (BMI) stratified by sex across 14 CheckMate clinical trials.

Author

McQuade, Jennifer Leigh, primary, Hammers, Hans J., additional, Furberg, Helena, additional, Engert, Andreas, additional, Andre, Thierry, additional, Blumenschein, George, additional, Tannir, Nizar M., additional, Baron, Ari David, additional, Larkin, James, additional, El-Khoueiry, Anthony B., additional, Carbone, David Paul, additional, Thomas, John-Michael, additional, Hennicken, Delphine, additional, Zoffoli, Roberto, additional, Reshef, Daniel, additional, Coffey, Mary, additional, and Motzer, Robert J., additional

Published
2020
Full Text
View/download PDF

238. Reply to H.J.A. Adams et al

Author

Fuchs, Michael, primary, Goergen, Helen, additional, Kobe, Carsten, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2020
Full Text
View/download PDF

239. Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group

Author

Eichenauer, Dennis A., primary, Plütschow, Annette, additional, Fuchs, Michael, additional, Sasse, Stephanie, additional, Baues, Christian, additional, Böll, Boris, additional, von Tresckow, Bastian, additional, Diehl, Volker, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2020
Full Text
View/download PDF

241. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies

Author

Aldin, Angela, additional, Umlauff, Lisa, additional, Estcourt, Lise J, additional, Collins, Gary, additional, Moons, Karel GM, additional, Engert, Andreas, additional, Kobe, Carsten, additional, von Tresckow, Bastian, additional, Haque, Madhuri, additional, Foroutan, Farid, additional, Kreuzberger, Nina, additional, Trivella, Marialena, additional, and Skoetz, Nicole, additional

Published
2020
Full Text
View/download PDF

246. Reduced Treatment Intensity in Patients with Early-Stage Hodgkinʼs Lymphoma

Author

Engert, Andreas, Plütschow, Annette, Eich, Hans Theodor, Lohri, Andreas, Dörken, Bernd, Borchmann, Peter, Berger, Bernhard, Greil, Richard, Willborn, Kay C., Wilhelm, Martin, Debus, Jürgen, Eble, Michael J., Sökler, Martin, Ho, Antony, Rank, Andreas, Ganser, Arnold, Trümper, Lorenz, Bokemeyer, Carsten, Kirchner, Hartmut, Schubert, Jörg, Král, Zdenek, Fuchs, Michael, Müller-Hermelink, Hans-Konrad, Müller, Rolf-Peter, and Diehl, Volker

Published
2010
Full Text
View/download PDF

247. Pretreatment Vitamin D Deficiency Is Associated With Impaired Progression-Free and Overall Survival in Hodgkin Lymphoma

Author

Borchmann, Sven, primary, Cirillo, Melita, additional, Goergen, Helen, additional, Meder, Lydia, additional, Sasse, Stephanie, additional, Kreissl, Stefanie, additional, Bröckelmann, Paul Jan, additional, von Tresckow, Bastian, additional, Fuchs, Michael, additional, Ullrich, Roland Tillmann, additional, and Engert, Andreas, additional

Published
2019
Full Text
View/download PDF

249. Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)

Author

Bröckelmann, Paul J, primary, Goergen, Helen, primary, Keller, Ulrich, primary, Meissner, Julia, primary, Ordemann, Rainer, primary, Halbsguth, Teresa V, primary, Sasse, Stephanie, primary, Sökler, Martin, primary, Kerkhoff, Andrea, primary, Mathas, Stephan, primary, Hüttmann, Andreas, primary, Bormann, Matthias, primary, Zimmermann, Andreas, primary, Fuchs, Michael, primary, von Tresckow, Bastian, primary, Baues, Christian, primary, Rosenwald, Andreas, primary, Klapper, Wolfram, primary, Kobe, Carsten, primary, Borchmann, Peter, primary, and Engert, Andreas, primary

Published
2019
Full Text
View/download PDF

250. Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial

Author

Bröckelmann, Paul J, primary, Plütschow, Annette, additional, Greil, Richard, additional, Zijlstra, Josée M, additional, Illidge, Timothy, additional, Fosså, Alexander, additional, Meissner, Julia, additional, Zimmermann, Andreas, additional, Mathas, Stephan, additional, Thol, Felicitas, additional, Fuchs, Michael, additional, Engert, Andreas, additional, and Baues, Christian, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results